JP2015523328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523328A5 JP2015523328A5 JP2015511443A JP2015511443A JP2015523328A5 JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5 JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100005310 CTLA4 Human genes 0.000 claims 21
- 101700054183 CTLA4 Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 3
- 102100019451 CD80 Human genes 0.000 claims 2
- 101700080477 CD80 Proteins 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
Claims (12)
- 野生型CTLA−4の配列番号35と比較して大きいヒトCD80結合親和性、大きい効力および/または大きい安定性を有する単離CTLA−4ポリペプチドであって、配列番号35のバリアントであるアミノ酸配列を含み、前記バリアントは、配列番号35中の以下のアミノ酸突然変異を含むポリペプチド:
I16におけるR;
A24におけるT;
S25におけるN;
G27におけるS;
L58におけるA;
S70におけるA;
M85におけるQ;および
K93におけるQ。 - 野生型CTLA−4の配列番号35と比較して大きいヒトCD80結合親和性、大きい効力および/または大きい安定性を有する単離CTLA−4ポリペプチドであって、
アミノ酸配列の配列番号43を含むポリペプチド。 - 野生型CTLA−4(配列番号35)よりも大きいヒトCD86結合親和性を有する、請求項1に記載のCTLA−4ポリペプチド。
- IgGFcアミノ酸配列にコンジュゲートしている、請求項1に記載のCTLA−4ポリペプチド。
- 前記IgGFcは、Fcエフェクター機能を低減させるように改変されたヒトIgG1Fcであり、天然ヒトIgG1Fcヒンジ領域を含む、請求項4に記載のCTLA−4ポリペプチド。
- 前記IgGFcアミノ酸配列は、配列番号59を含む、請求項4に記載のCTLA−4ポリペプチド。
- NCIMBアクセッション番号41948のもとで寄託された核酸によりコードされる1299CTLA−4−Igアミノ酸配列を含む、単離CTLA−4ポリペプチド。
- 核酸を含有する宿主細胞であって、前記核酸は、NCIMBアクセッション番号41948のもとで寄託された1299CTLA−4−Ig核酸配列を含む宿主細胞。
- 請求項7に記載のCTLA−4ポリペプチド;および
1つ以上の医薬賦形剤を含む組成物。 - 前記CTLA−4ポリペプチドは、配列番号59を含むIgGFcアミノ酸配列にコンジュゲートしている、請求項9に記載の組成物。
- 配列番号43のCTLA−4ポリペプチドアミノ酸配列またはNCIMBアクセッション番号41948のもとで寄託された核酸によりコードされるCTLA−4アミノ酸配列の突然変異によりさらなるCTLA−4ポリペプチドを産生する方法であって:
アミノ酸配列の配列番号43またはNCIMBアクセッション番号41948のもとで寄託された核酸によりコードされるCTLA−4アミノ酸配列を含み、またはそれからなるCTLA−4ポリペプチドを提供すること;
1つ以上の突然変異を前記アミノ酸配列中に導入してさらなるCTLA−4ポリペプチドを提供すること;
前記さらなるCTLA−4ポリペプチドの安定性、親和性および/または効力を試験すること;ならびに
前記さらなるCTLA−4ポリペプチドを、1つ以上の医薬賦形剤を含む組成物に配合すること
を含む方法。 - 前記さらなるCTLA−4ポリペプチドがFc領域にコンジュゲートしている、請求項11に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645686P | 2012-05-11 | 2012-05-11 | |
US61/645,686 | 2012-05-11 | ||
PCT/US2013/030179 WO2013169338A1 (en) | 2012-05-11 | 2013-03-11 | Ctla-4 variants |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015523328A JP2015523328A (ja) | 2015-08-13 |
JP2015523328A5 true JP2015523328A5 (ja) | 2016-03-31 |
JP6228971B2 JP6228971B2 (ja) | 2017-11-08 |
Family
ID=49551120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015511443A Active JP6228971B2 (ja) | 2012-05-11 | 2013-03-11 | Ctla−4バリアント |
Country Status (17)
Country | Link |
---|---|
US (2) | US9884902B2 (ja) |
EP (2) | EP3207938B1 (ja) |
JP (1) | JP6228971B2 (ja) |
KR (1) | KR102133060B1 (ja) |
CN (2) | CN104302309B (ja) |
AU (1) | AU2013260172B2 (ja) |
BR (1) | BR112014026718B1 (ja) |
CA (1) | CA2868748C (ja) |
DK (1) | DK3207938T3 (ja) |
ES (1) | ES2777778T3 (ja) |
HK (1) | HK1209644A1 (ja) |
HU (1) | HUE048925T2 (ja) |
MX (1) | MX355234B (ja) |
PL (1) | PL3207938T3 (ja) |
RU (1) | RU2671465C2 (ja) |
SG (2) | SG11201405968SA (ja) |
WO (1) | WO2013169338A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2777778T3 (es) * | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
DK2867251T3 (da) * | 2012-06-29 | 2019-11-25 | Bristol Myers Squibb Co | Fremgangsmåder til reduktion af glycoproteinaggregering |
WO2014138188A1 (en) * | 2013-03-07 | 2014-09-12 | The General Hospital Corporation | Human ctla4 mutants and use thereof |
KR20160113268A (ko) * | 2014-01-28 | 2016-09-28 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 이기능 융합단백질,이의 제조방법 및 용도 |
US10689423B2 (en) | 2015-01-13 | 2020-06-23 | City Of Hope | CTLA4-binding protein peptide-linker masks |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
US11351224B2 (en) | 2015-08-21 | 2022-06-07 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Pharmaceutical composition for preventing and treating transplant rejection |
EP3336100B1 (en) | 2015-08-21 | 2021-01-13 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient |
WO2017034244A1 (ko) * | 2015-08-21 | 2017-03-02 | 한양대학교 산학협력단 | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 |
AU2016323069A1 (en) * | 2015-09-14 | 2018-04-12 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
BR112019018747A2 (pt) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
RU2770209C2 (ru) | 2017-05-24 | 2022-04-14 | ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ | Терапевтические антитела против лиганда cd40 |
KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
AU2018351000B2 (en) | 2017-10-18 | 2023-11-30 | Alpine Immune Sciences, Inc. | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods |
CA3106384A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
WO2020210596A1 (en) * | 2019-04-10 | 2020-10-15 | University Of Kentucky Research Foundation | Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use |
US20230062096A1 (en) * | 2020-01-11 | 2023-03-02 | Yale University | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency |
AU2021252514A1 (en) * | 2020-04-06 | 2022-11-10 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
WO2023057995A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
WO2023112001A2 (en) * | 2021-12-17 | 2023-06-22 | Kashiv Biosciences, Llc | An improved assay method for determining the potency of recombinant protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
AU3804397A (en) * | 1996-06-14 | 1998-01-07 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
SK288131B6 (sk) * | 2000-05-26 | 2013-10-02 | Bristol-Myers Squibb Company | CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2007007654A1 (ja) | 2005-07-07 | 2007-01-18 | Toshiba Lighting & Technology Corporation | 放電灯点灯装置および電球形蛍光ランプ |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
ES2399088T3 (es) * | 2007-11-01 | 2013-03-25 | Perseid Therapeutics Llc | Polipéptidos y ácidos nucleicos inmunosupresores |
ES2586579T3 (es) | 2010-02-19 | 2016-10-17 | Xencor, Inc. | Nuevas inmunoadhesinas de CTLA4-IG |
TW201134481A (en) * | 2010-03-12 | 2011-10-16 | Abbott Biotherapeutics Corp | CTLA4 proteins and their uses |
ES2777778T3 (es) * | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
-
2013
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en active Application Filing
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active IP Right Grant
-
2015
- 2015-10-28 HK HK15110585.3A patent/HK1209644A1/xx unknown
-
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015523328A5 (ja) | ||
Bermudez-Humaran et al. | An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci | |
Tao et al. | Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
HRP20190689T1 (hr) | Muteini suznog lipokalina koji vežu il-4r alfa | |
JP2010529860A5 (ja) | ||
IL275307A (en) | SYNTAC polypeptides and their uses | |
WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
JP2016532693A5 (ja) | ||
CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
JP2018532382A5 (ja) | ||
JP2016156828A5 (ja) | ||
JP2019522465A5 (ja) | ||
JP2015532654A5 (ja) | ||
JP2016526909A5 (ja) | ||
JP2012095652A5 (ja) | ||
JP2015525217A5 (ja) | ||
JP2009511000A5 (ja) | ||
JP2013519721A5 (ja) | ||
JP2015511637A5 (ja) | ||
CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
JP2019502404A5 (ja) | ||
Haugen et al. | Mutational analysis of residues in the helical region of the class IIa bacteriocin pediocin PA-1 | |
WO2010079991A3 (ko) | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 | |
JP2017221201A5 (ja) |